The FDA has approved Liletta (levonorgestrel-releasing intrauterine system) 52 mg for the prevention of pregnancy for up to 4 years. Liletta is manufactured by Allergan plc, Dublin, Ireland, and Medicines360, San Francisco, CA.
Indications: Liletta is a sterile, levonorgestrel-releasing intrauterine system indicated for prevention of pregnancy for up to 4 years.
Dosage and administration: To be inserted by a trained health care provider using strict aseptic technique. Follow insertion instructions exactly as described. Patient should be re-examined and evaluated 4 to 6 weeks after insertion and once a year thereafter, or more frequently if clinically indicated.
Adverse reactions: The most common adverse reactions reported in clinical trials (>10% users) are vaginal bacterial infections, vulvovaginal mycotic infections, and acne.
FDA approves Medicines360’s sNDA for Liletta (levonorgestrel-releasing intrauterine system) 52 mg to prevent pregnancy for up to four years. [news release]. San Francisco, CA: Medicines360; August 7, 2017; http://medicines360.org/news/fda-approves-medicines360-s-snda-for-lilett.... Accessed August 10, 2017.
This Week's Must Reads
Must Reads in Contraception
Bleeding and Spotting with the LNG 13.5 mg IUS, Contraception; ePub 2019 Mar 1; Shimoni, et al
Contraception and Chronic Opioid Prescriptions, Contraception; ePub 2019 Feb 11; Ray-Griffith, et al
Hormonal Contraception & Coexisting Medical Conditions, Obstet Gynecol; ePub 2019 Feb; Allen, et al
Contraceptive Switching & Discontinuation, Am J Obstet Gynecol; ePub 2018 Dec 18; Simmons, et al
Efficacy of a Levonorgestrel 52-mg IU System, Obstet Gynecol; ePub 2018 Dec 4; Teal, et al